secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001689375-22-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Therapeutics reports Q2 2022 net loss of $23.2M; cash runway into 2H 2024
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $244.3M as of June 30, 2022, sufficient into 2H 2024.
- Net loss $23.2M vs $9.9M in Q2 2021; R&D $16.2M (up from $6.8M), G&A $7.3M (up from $3.1M).
- On track to file IND for ENTR-601-44 (Duchenne) in Q4 2022; ENTR-701 named as first DM1 clinical candidate.
- Appointed Karla MacDonald as Chief Corporate Affairs Officer.
- Entered collaboration with Myotonic Dystrophy Clinical Research Network for natural history study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937522000010/0001689375-22-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937522000010/trda-20220811.htm
  HTML page:      https://secwatch.observer/filing/0001689375-22-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer